# RIN Institute

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rin-institute

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: https://rinmab.co.jp
- Total disclosed funding: $1.9M
- Latest round: Series B (Dec 4, 2020)
- Investors on record: 2

## About

Based in Japan, RIN Institute Inc. is engaged in the development of innovative antibody therapeutics that enhance cancer diagnosis and treatment, focusing on improving outcomes for patients in the oncology sector.RIN Institute Inc. specializes in developing antibody therapeutics for cancer treatment, having been founded in 2016 in Tokyo, Japan. The company has completed 3 deals, with its most recent funding round occurring on May 31, 2023, when it raised JPY 500.000 mn from Alfresa Holdings. The total amount raised so far is JPY 500.000 mn.???????? specializes in the development of innovative antibody therapeutics aimed at enhancing cancer diagnosis and treatment. Their core product offerings include a range of proprietary monoclonal antibodies designed to target specific cancer cells, thereby improving both the efficacy and safety of cancer therapies. The products are intended to address critical challenges in oncology, such as late-stage diagnosis and limited treatment options for patients. The company aims to deliver these novel therapies to healthcare providers operating primarily within the Asian markets, focusing on regions with a growing demand for advanced cancer treatment options. Their client base consists of hospitals, oncology clinics, and research institutions that utilize these therapeutics to provide better outcomes for patients battling cancer.???????? generates revenue through strategic partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies. The transaction structure typically involves licensing agreements and joint ventures, allowing the company to distribute its antibody products effectively within the oncology market. Revenue is derived from both upfront payments and milestone payments associated with the development and commercialization of their flagship antibody products. These arrangements are designed to foster long-term relationships with clients, ensuring a steady flow of income as the products advance through clinical trials and eventual market launch. The firm focuses on creating sustainable partnerships that enable them to reach a broader audience while enhancing their financial stability.In May 2023, RIN Institute Inc. raised JPY 500.000 mn in venture funding from Alfresa Holdings Corporation. The company plans to utilize these funds to further promote the ongoing Phase 1 study of its anti-TMEM180 antibody. They are focused on expanding their product pipeline and developing new antibody therapeutics, targeting enhanced market penetration in Asian regions with high demand for advanced oncology solutions.

## Funding rounds

- Series B, Dec 4, 2020, $1.9M — Fast Track Initiative, UTokyo Innovation Platform
- Series A, Jun 25, 2018 — Fast Track Initiative

## Investors

- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series A, Series B
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series B